Get the Stockscreener App
252.27
0.76%
-1.94
After Hours:
252.27
Penumbra Inc stock is traded at $252.27, with a volume of 1.08M.
It is down -0.76% in the last 24 hours and down -1.70% over the past month.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
See More
Previous Close:
$254.21
Open:
$250.5
24h Volume:
1.08M
Relative Volume:
2.15
Market Cap:
$9.77B
Revenue:
$1.24B
Net Income/Loss:
$42.23M
P/E Ratio:
237.99
EPS:
1.06
Net Cash Flow:
$150.33M
1W Performance:
+9.60%
1M Performance:
-1.70%
6M Performance:
-5.51%
1Y Performance:
+50.98%
1-Day Range:
$249.11
$261.81
1-Week Range:
$225.48
$261.81
52-Week Range:
$160.18
$310.00
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
252.27 | 9.91B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Should You Invest in Penumbra (PEN)? - Insider Monkey
Penumbra, Inc. (NYSE:PEN) Q2 2025 Earnings Call Transcript - Insider Monkey
Penumbra Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Is it the right time to buy Penumbra Inc. stockStock Strategy Tracker For Every Investor - jammulinksnews.com
Penumbra Inc. Reports Strong Q2 Earnings with Growth in U.S. Thrombectomy - TipRanks
Penumbra Surges 11.9% on Q2 Earnings Beat and Margin Expansion as $300M Volume Pushes It to 407th Trading Rank - AInvest
Penumbra, Inc. To Present At The Canaccord Genuity 45th Annual Growth Conference - Barchart.com
Penumbra (PEN) Shares Skyrocket, What You Need To Know - TradingView
Penumbra stock price target lowered to $325 at RBC Capital on margin outlook - Investing.com India
Penumbra: Truist Securities maintains a 'Buy' Rating, The Target Price is $310 - AInvest
Penumbra stock price target raised to $335 from $330 at UBS on solid growth - Investing.com
Penumbra price target raised to $335 from $330 at UBS - TipRanks
Why Did Penumbra Stock Soar 14.46%? - AInvest
S&P 500 Futures Climb in Premarket Trading; Penumbra, Marvell Technology Lead - Barron's
Why Penumbra Inc. stock attracts strong analyst attentionScalable Portfolio Growth Suggestions Released - metal.it
Penumbra Inc (PEN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo.co
Penumbra outlines 13% to 15% revenue growth target for 2025 as thrombectomy adoption accelerates - MSN
Penumbra, Inc. Reports Strong Q2 2025 Results - TipRanks
Penumbra 2025 Q2 Earnings Strong Performance as Net Income Swings to Profit - AInvest
Penumbra's Q2 2025: Dissecting Contradictions on Thunderbolt FDA Review, Revenue Guidance, and Market Dynamics - AInvest
Penumbra Lifts Revenue Forecast As US Demand Climbs - Finimize
Penumbra, Inc. shares rise 11.44% after-hours after Q2 earnings and revenue beat expectations. - AInvest
Penumbra, Inc. shares rise 9.46% after-hours after reporting Q2 Non-GAAP earnings and revenue growth. - AInvest
Founder-led focus meets demographic tailwinds: A decade-long runway - Livewire Markets
Earnings call transcript: Penumbra Inc. beats Q2 2025 estimates - Investing.com Australia
Earnings call transcript: Penumbra Inc. beats Q2 2025 estimates By Investing.com - Investing.com South Africa
Penumbra (PEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Penumbra’s (NYSE:PEN) Q2: Strong Sales, Stock Soars - TradingView
Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Penumbra: Q2 Earnings Snapshot - San Antonio Express-News
Penumbra shares surge as thrombectomy leader beats Q2 expectations - Investing.com Australia
Penumbra Inc earnings beat by $0.03, revenue topped estimates - Investing.com Australia
Penumbra, Inc. Reports Second Quarter 2025 Financial Results - TradingView
Penumbra Earnings: VTE Sales Soar 42%, Medical Device Giant Lifts Revenue Forecast to $1.37B - Stock Titan
Is It Too Early to Call Recovery in Penumbra Inc.Wealth Building Stock Market Ideas Based on Momentum - metal.it
Penumbra Inc. Sees Spike in Bullish Option FlowLow Drawdown Real Time Trading Tips Shared - metal.it
What are analysts’ price targets for Penumbra Inc. in the next 12 monthsDaily Trading Report For Smart Trading - jammulinksnews.com
How strong is Penumbra Inc. company’s balance sheetValue Investing Opportunities For 2025 - jammulinksnews.com
Penumbra's CEO Stock Sale: Strategic Liquidity or Market Signal? - AInvest
What are Penumbra Inc. company’s key revenue driversPhenomenal capital appreciation - jammulinksnews.com
What are the technical indicators suggesting about Penumbra Inc.Unmatched profit growth - jammulinksnews.com
Penumbra (PEN) Earnings Report: Is This Medical Innovator Poised to Sustain Its Earnings Beat Momentum? - AInvest
Penumbra (PEN) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
What makes Penumbra Inc. stock price move sharplyDiscover high-impact stocks for your portfolio - jammulinksnews.com
What is the risk reward ratio of investing in Penumbra Inc. stockLightning-fast capital gains - jammulinksnews.com
Is Penumbra Inc. a growth stock or a value stockConsistent high-yield stocks - jammulinksnews.com
Is Penumbra Inc. a good long term investmentDynamic capital growth - jammulinksnews.com
Penumbra CEO Adam Elsesser sells $3.7m in shares By Investing.com - Investing.com Canada
Penumbra CEO Adam Elsesser sells $3.7m in shares - Investing.com Australia
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):